The Latest Advances In The Treatment of Melanoma

The presentation discusses recent advances in melanoma treatment, highlighting the rising incidence rates of the disease, particularly in states like California and Florida, and projecting significant increases in cases by 2040. Sentinel node biopsy remains crucial for staging in patients with melanomas >0.8mm thick, helping to determine the need for adjuvant therapy, although the challenge lies in identifying patients who could safely avoid the procedure. Recent research aims to use gene expression profiling to predict sentinel node positivity. For patients with positive sentinel nodes, adjuvant therapy with pembrolizumab has shown a notable reduction in distant metastasis. Additionally, neoadjuvant therapy is emerging as a beneficial approach where treatment occurs prior to surgery, demonstrating improved outcomes in terms of recurrence and allowing for the potential avoidance of complete lymph node dissections. Furthermore, advances in treating unresectable stage IV melanoma, including the recent FDA approval of tumor-infiltrating lymphocytes therapies, offer hope, with significant survival rates observed in previously refractory cases. Overall, the field is evolving with ongoing research and promising treatment avenues.